Abstract: . . .  activity and clinical implications. J Clin Oncol, 2000, 18 , 1135-1149. 68. R ANDAL J. Antiangiogenesis drugs target specific cancers , mechanisms. J Natl Cancer Inst, 2000, 92 , 520-522. 69. S TADLER WM, K UZEL T, S HAPIRO C et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. J Clin Oncol, 1999, 17 , 2541-2545. Page 17 ACTUALITÉS DANS LE CANCER DU REIN MÉTASTATIQUE 283 70. E ISEN T, B OSHOFF C, M AK I et al. Continuous low-dose thalidomide : a phase II study in advanced melanoma, renal cell, ovarian and breast cancer . Br J Cancer , 2000, 82 , 812-817. 71. E SCUDIER B, L ASSAU N, C OUANET D et al. Phase II trial of Thalidomide in renal cell carcinoma. Ann Oncol, 2002, 13 , 1029-1035. 72. . . .
. . .  clinical implications. J Clin Oncol, 2000, 18 , 1135-1149. 68. R ANDAL J. Antiangiogenesis drugs target specific cancers , mechanisms. J Natl Cancer Inst, 2000, 92 , 520-522. 69. S TADLER WM, K UZEL T, S HAPIRO C et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. J Clin Oncol, 1999, 17 , 2541-2545. Page 17 ACTUALITÉS DANS LE CANCER DU REIN MÉTASTATIQUE 283 70. E ISEN T, B OSHOFF C, M AK I et al. Continuous low-dose thalidomide : a phase II study in advanced melanoma, renal cell, ovarian and breast cancer . Br J Cancer , 2000, 82 , 812-817. 71. E SCUDIER B, L ASSAU N, C OUANET D et al. Phase II trial of Thalidomide in renal cell carcinoma. Ann Oncol, 2002, 13 , 1029-1035. 72. B ATIST G, . . .
. . .  rate accuracy in oncological trials : reasons for interobserver variability. J Clin Oncol, 1997, 15 , 3507-3514. 80. O LIVER RT. Renal cell cancer : is there long-term survival advantage from cytokine treatment ? Eur J Cancer , 1994, 30A , 1214-1216. 81. J ONES M, P HILIP T, P ALMER P et al. The impact of Interleukin-2 on survival in renal cancer : a multivariate analysis. Cancer Biother, 1993, 8 , 275-288. 82. F ISHMAN M, S EIGNE J, A NTONIA S. Novel therapies for renal cell carcinoma. Expert Opin Investig Drugs, 2001, 10 , 1033-1044.  . . .
. . .  implications. J Clin Oncol, 2000, 18 , 1135-1149. 68. R ANDAL J. Antiangiogenesis drugs target specific cancers , mechanisms. J Natl Cancer Inst, 2000, 92 , 520-522. 69. S TADLER WM, K UZEL T, S HAPIRO C et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal cell carcinoma. J Clin Oncol, 1999, 17 , 2541-2545. Page 17 ACTUALITÉS DANS LE CANCER DU REIN MÉTASTATIQUE 283 70. E ISEN T, B OSHOFF C, M AK I et al. Continuous low-dose thalidomide : a phase II study in advanced melanoma, renal cell, ovarian and breast cancer . Br J Cancer , 2000, 82 , 812-817. 71. E SCUDIER B, L ASSAU N, C OUANET D et al. Phase II trial of Thalidomide in renal cell carcinoma. Ann Oncol, 2002, 13 , 1029-1035. 72. B ATIST G, P ATENAUDE F, C HAMPAGNE . . .
--3000,4,375,3092,52007